Health Canada Allow Physicians to Request Banned Drugs on Behalf of Patients

0.7 min readPublished On: January 12th, 2022By

OTTAWA–In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.

Through an amendment to federal regulations, Health Canada is now allowing physicians to request access to restricted drugs on behalf of patients through the Special Access Program.

This program is meant to streamline access to special treatments for patients with serious or life-threatening conditions in instances where other therapies have failed or are unsuitable.

While the official communication made sure to note that “this regulatory change will not result in large-scale authorization for access to restricted drugs,” the event can be seen as an official acknowledgement of MDMA and psilocybin’s therapeutic potential and eventually lead to further decriminalization measures.

Benzinga carried the full story here.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

ACS Laboratory Announces New THCOa Safety Bundle

January 19th, 2022|

BOCA RATON, Fla. - ACS Laboratory, hemp and cannabis testing facility in the eastern U.S., has developed the THCOa Safety Bundle Test, a testing panel to test for THC-O Acetate (THCOa), acetic anhydride and other ...

Curaleaf Completes Acquisition of Bloom Dispensaries

January 19th, 2022|

WAKEFIELD, Mass. - Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF), an international provider of consumer products in cannabis, announced the completion of its previously announced acquisition of Bloom Dispensaries, a single state cannabis operator ...